Testing N-Acetyl Cysteine and Alpha Lipoic Acid in Beta Thalassemia
Tests two drugs, N-acetyl cysteine and alpha lipoic acid, in adults with beta thalassemia.
Plain-language title generated from the registry record
Registry title: Evaluating the Effect of N-Acetyl Cysteine and Alpha Lipoic Acid in Patients With Beta Thalassemia
Key facts
- Where
- Tanta, EgyptSee the site
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07157722, who can take part
Where in Egypt
- Faculty of Pharmacy, Tanta UniversityTanta, EgyptNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tanta University
- Trial code
- NCT07157722
- Record updated
- 5 September 2025
- Original description
The current study is to investigate the potential roles of N-acetyl cysteine and Alpha-lipoic acid in patients with beta-thalassemia.Read full original descriptionShow less
The Potential Role of N-Acetyl Cysteine or Alpha-Lipoic Acid as Adjuvant Therapies in the Treatment of Patients With Beta Thalassemia
The current study is to investigate the potential roles of N-acetyl cysteine and Alpha-lipoic acid in patients with beta-thalassemia.
Inclusion: Patients with beta-thalassemia who will receive conventional thalassemia management; Both genders; Age ≥ 18 years old.
Exclusion: Patients with a prior history of significant cardiovascular diseases, such as coronary artery disease, myocardial infarction, or stroke; Patients who will be non-compliant with the prescribed therapy; Patients who will receive antioxidant or anti-inflammatory medications; Patients with familial hypercholesterolemia or history of premature atherosclerosis; Patients with diabetes; Patients with inflammatory diseases, such as Systemic lupus erythematous, rheumatoid arthritis and inflammatory bowel disease; Patients with oxidative stress related diseases, such as Alzheimer, Parkinson, COPD and cancer; Patients with severe renal dysfunction; Patients with severe hepatic dysfunction; Patients with other hemoglobinopathies; Pregnant women; Obese patients.